Display options
Cite
Hinson AR, Jones R, Crose LE, et al. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013;3:183doi: 10.3389/fonc.2013.00183.
Hinson, A. R., Jones, R., Crose, L. E., Belyea, B. C., Barr, F. G., & Linardic, C. M. (2013). Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Frontiers in oncology, 3183. https://doi.org/10.3389/fonc.2013.00183
Hinson, Ashley R P, et al. "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls." Frontiers in oncology vol. 3 (2013): 183. doi: https://doi.org/10.3389/fonc.2013.00183
Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013 Jul 17;3:183. doi: 10.3389/fonc.2013.00183. eCollection 2013. PMID: 23882450; PMCID: PMC3713458.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2013 Jul 17;3:183. doi: 10.3389/fonc.2013.00183. eCollection 2013.

Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.

Frontiers in oncology

Ashley R P Hinson, Rosanne Jones, Lisa E S Crose, Brian C Belyea, Frederic G Barr, Corinne M Linardic

Affiliations

  1. Department of Pediatrics, Duke University Medical Center , Durham, NC , USA.

PMID: 23882450 PMCID: PMC3713458 DOI: 10.3389/fonc.2013.00183

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite intergroup clinical trials conducted in Europe and North America, outcomes for high risk patients with this disease have not significantly improved in the last several decades, and survival of metastatic or relapsed disease remains extremely poor. Accrual into new clinical trials is slow and difficult, so in vitro cell-line research and in vivo xenograft models present an attractive alternative for preclinical research for this cancer type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, karyotypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS research has important implications for outcomes. There are also potential pitfalls in using certain cell lines including contamination with murine stromal cells, cross-contamination between cell lines, discordance between the cell line and its associated original tumor, imposter cell lines, and nomenclature errors that result in the circulation of two or more presumed unique cell lines that are actually from the same origin. These pitfalls can be avoided by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific fusion products, and short tandem repeat analysis.

Keywords: alveolar; embryonal; human cell line; rhabdomyosarcoma; xenograft

References

  1. Br J Cancer. 1991 Jun;63(6):879-84 - PubMed
  2. Cancer Res. 1993 Nov 15;53(22):5535-41 - PubMed
  3. J Natl Cancer Inst. 2010 Feb 24;102(4):271-4 - PubMed
  4. Hum Cell. 1995 Mar;8(1):35-41 - PubMed
  5. Hum Mol Genet. 1996 Jan;5(1):15-21 - PubMed
  6. Cancer. 1969 Sep;24(3):520-6 - PubMed
  7. Pediatr Res. 2003 Nov;54(5):718-23 - PubMed
  8. FASEB J. 2005 Mar;19(3):434-6 - PubMed
  9. Br J Cancer. 2010 Jun 8;102(12):1769-77 - PubMed
  10. Mol Cancer Ther. 2009 Nov;8(11):3024-35 - PubMed
  11. Nat Genet. 1993 Nov;5(3):230-5 - PubMed
  12. Nat Genet. 1993 Feb;3(2):113-7 - PubMed
  13. Genes Chromosomes Cancer. 1992 Nov;5(4):299-310 - PubMed
  14. Cytogenet Cell Genet. 2001;95(3-4):134-42 - PubMed
  15. Cancer Res. 1998 Nov 15;58(22):5009-13 - PubMed
  16. Cancer Res. 1987 Dec 1;47(23):6288-93 - PubMed
  17. Eur J Pediatr. 1988 Oct;148(1):69-71 - PubMed
  18. Cancer Genet Cytogenet. 2003 Mar;141(2):138-42 - PubMed
  19. Cancer Res. 2007 Jul 15;67(14):6691-9 - PubMed
  20. Clin Cancer Res. 2012 Jul 15;18(14):3780-90 - PubMed
  21. J Natl Cancer Inst. 1978 May;60(5):979-84 - PubMed
  22. Oncogene. 2008 Nov 20;27(51):6550-60 - PubMed
  23. Jpn J Cancer Res. 1986 Nov;77(11):1062-5 - PubMed
  24. Curr Top Dev Biol. 2011;94:197-234 - PubMed
  25. Pediatr Blood Cancer. 2011 Feb;56(2):239-49 - PubMed
  26. J Clin Oncol. 1999 Nov;17(11):3487-93 - PubMed
  27. Virchows Arch. 1995;426(4):385-91 - PubMed
  28. J Natl Cancer Inst. 1982 Mar;68(3):437-43 - PubMed
  29. Cancer Res. 1996 Jul 15;56(14):3220-4 - PubMed
  30. J Pharmacol Exp Ther. 1998 Aug;286(2):1066-73 - PubMed
  31. Br J Cancer. 1986 Dec;54(6):1009-14 - PubMed
  32. Eur J Cancer Clin Oncol. 1984 Jul;20(7):955-60 - PubMed
  33. Med Pediatr Oncol. 2000 Aug;35(2):96-103 - PubMed
  34. Cancer Genet Cytogenet. 2004 Jan 1;148(1):35-43 - PubMed
  35. Cancer Genet Cytogenet. 2000 Sep;121(2):139-45 - PubMed
  36. Cancer Res. 1982 Feb;42(2):535-9 - PubMed
  37. Cancer Res. 1990 Mar 1;50(5):1455-8 - PubMed
  38. Cancer Res. 1987 Aug 15;47(16):4501-7 - PubMed
  39. Anticancer Res. 1989 Nov-Dec;9(6):1943-9 - PubMed
  40. Cancer Res. 2010 Jan 15;70(2):762-71 - PubMed
  41. Cancer Genet Cytogenet. 1991 Jul 1;54(1):83-9 - PubMed
  42. Cancer. 2009 Sep 15;115(18):4218-26 - PubMed
  43. In Vitro Cell Dev Biol. 1990 Oct;26(10):971-7 - PubMed
  44. Cancer Genet Cytogenet. 1998 Apr 1;102(1):32-9 - PubMed
  45. Clin Cancer Res. 2008 Jul 15;14(14):4572-83 - PubMed
  46. J Transl Med. 2012 Jun 18;10:125 - PubMed
  47. Genes Chromosomes Cancer. 1996 Dec;17(4):254-9 - PubMed
  48. Oncogene. 1999 Dec 9;18(52):7559-65 - PubMed
  49. J Clin Invest. 2002 Oct;110(7):923-32 - PubMed
  50. Cancer Res. 1992 Dec 1;52(23):6431-9 - PubMed
  51. Am J Cancer Res. 2012;2(2):141-52 - PubMed
  52. J Pediatr Surg. 2007 Aug;42(8):1396-402 - PubMed
  53. Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 - PubMed
  54. Cytogenet Cell Genet. 1987;45(3-4):148-55 - PubMed
  55. Oncogene. 2002 Aug 8;21(34):5193-203 - PubMed
  56. Clin Cancer Res. 2009 Jun 15;15(12):4077-84 - PubMed
  57. Carcinogenesis. 1989 May;10(5):899-905 - PubMed
  58. Mol Cell Biol. 1996 Sep;16(9):5048-57 - PubMed
  59. Acta Pathol Jpn. 1986 Oct;36(10):1495-505 - PubMed
  60. Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 - PubMed
  61. Cancer Res. 2011 Dec 15;71(24):7471-80 - PubMed
  62. Nature. 1989 Jul 13;340(6229):106 - PubMed
  63. Pediatr Blood Cancer. 2008 Mar;50(3):703-6 - PubMed
  64. Am J Pathol. 1986 Oct;125(1):208-17 - PubMed
  65. Int J Oncol. 2000 Jul;17(1):119-25 - PubMed
  66. Leukemia. 2003 Feb;17(2):416-26 - PubMed
  67. Oncogene. 2014 Apr 10;33(15):1877-89 - PubMed
  68. Pediatr Blood Cancer. 2007 Dec;49(7):928-40 - PubMed
  69. Clin Cancer Res. 2012 Feb 1;18(3):748-57 - PubMed
  70. Clin Cancer Res. 1999 Nov;5(11):3617-31 - PubMed
  71. Jpn J Cancer Res. 1998 May;89(5):525-32 - PubMed
  72. Int J Cancer. 1990 Apr 15;45(4):705-11 - PubMed
  73. Genes Chromosomes Cancer. 2009 Nov;48(11):975-82 - PubMed
  74. Biochem Biophys Res Commun. 2004 May 28;318(2):594-600 - PubMed
  75. Br J Cancer. 1992 Apr;65(4):519-22 - PubMed
  76. Cancer Res. 2003 Apr 1;63(7):1508-14 - PubMed
  77. Cancer Res. 1990 Sep 15;50(18):6002-9 - PubMed
  78. PLoS One. 2011;6(5):e19506 - PubMed
  79. Cancer Genet Cytogenet. 1992 Jul 15;61(2):214-5 - PubMed
  80. Cancer Res. 2007 Jan 1;67(1):32-40 - PubMed
  81. Br J Cancer. 1989 Feb;59(2):160-4 - PubMed
  82. Int J Cancer. 2013 Feb 15;132(4):795-806 - PubMed
  83. Cancer Res. 1992 Apr 15;52(8):2243-7 - PubMed
  84. Br J Cancer. 2000 Mar;82(6):1239-45 - PubMed
  85. Hum Cell. 2007 May;20(2):39-51 - PubMed
  86. Methods Mol Med. 2004;88:43-55 - PubMed
  87. Br J Cancer. 1986 Jul;54(1):83-90 - PubMed

Publication Types

Grant support